State Street
SKYE icon

State Street’s Skye Bioscience SKYE Stock Holding History

State Street’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.3K Hold
75,326
– – ﹤0.01% 4139
2025
Q4 		$56.5K Hold
75,326
– – ﹤0.01% 4133
2025
Q3 		$296K Buy
75,326
+8,626
+13% +$32.6K ﹤0.01% 3793
2025
Q2 		$279K Sell
66,700
-303,214
-82% -$628K ﹤0.01% 3747
2025
Q1 		$588K Sell
369,914
-4,590
-1% -$12.5K ﹤0.01% 3554
2024
Q4 		$1.06M Buy
374,504
+20,299
+6% +$84.8K ﹤0.01% 3481
2024
Q3 		$1.38M Buy
354,205
+23,201
+7% +$130K ﹤0.01% 3420
2024
Q2 		$2.65M Buy
+331,004
New +$3.93M ﹤0.01% 3204

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street's SKYE Position: Q1 2026 in Review

State Street held its Skye Bioscience (SKYE) position steady in Q1 2026 at 75,326 shares worth $46.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4139.

State Street first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.65M in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • State Street held 75,326 shares of Skye Bioscience worth $46.3K as of Q1 2026.
  • State Street left its Skye Bioscience share count unchanged in Q1 2026.
  • Skye Bioscience made up ﹤0.01% of State Street's portfolio in Q1 2026, its #4139 holding.
  • State Street first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • State Street's Skye Bioscience position peaked at $2.65M in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.